Literature DB >> 30286468

Is Early Complement Activation in Renal Transplantation Associated with Later Graft Outcome?

Steffen Bobka1, Nadja Ebert1, Eloed Koertvely2, Johannes Jacobi3, Michael Wiesener3, Maike Büttner-Herold1, Kerstin Amann1, Christoph Daniel4.   

Abstract

BACKGROUND/AIMS: Complement activation is important in post-transplantation renal injury, but data on its role as predictor of transplant outcome/complications when assessed in donor kidneys are lacking.
METHODS: In human renal transplant biopsies with delayed graft function (DGF, n=12), antibody mediated rejection (ABMR, n=8), T-cell mediated rejection (TCMR, n=11), 1 year protocol biopsies (control, n=10) and corresponding zero-biopsies we performed immunohistochemical analyses of 6 complement factors using FFPE sections and correlated the findings with kidney function, as assessed by serum creatinine, and morphological changes including interstitial fibrosis and tubular atrophy (IF/TA).
RESULTS: In DGF, TCMR and ABMR significant complement deposition was observed, which was less pronounced in corresponding zero-biopsies. Zero-biopsies with subsequent ABMR showed glomerular complement factor D and C3c expression. Moreover, glomerular C3c and C9 and tubular MASP-2 and Collectin-11 expression in zero-biopsies significantly correlated with serum creatinine at diagnosis of DGF, TCMR or ABMR. Glomerular C1q was significantly increased in ABMR, but not in DGF and TCMR. In contrast, peritubular C1q was significantly enhanced in DGF and TCMR compared to zero-biopsies. Using C3d as a surrogate marker for complement activity we could confirm that stained complement factors are frequently associated with complement activity.
CONCLUSION: Complement deposition strongly correlated with histopathological changes observed in renal transplants. All 3 complement pathways were operational in biopsies with DGF, TCMR and ABMR albeit with differential abundance and localization. Since complement deposition in zero-biopsies correlated with graft function and morphological changes, early specific complement inhibition in renal transplantation may be a new therapeutic option to prevent graft loss.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  C1q; C3c; C3d; C9; CFD; Collectin 11; Complement; MASP-2; Renal biopsy; Renal transplantation

Mesh:

Year:  2018        PMID: 30286468     DOI: 10.1159/000494014

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  10 in total

1.  The synergism of B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) attenuated acute T-cell mediated rejection and prolonged renal graft survival.

Authors:  Hengcheng Zhang; Zijie Wang; Jiayi Zhang; Xiang Zhang; Zeping Gui; Li Sun; Haiwei Yang; Ruoyun Tan; Min Gu
Journal:  Transl Androl Urol       Date:  2020-10

2.  B-cell Deficiency Attenuates Transplant Glomerulopathy in a Rat Model of Chronic Active Antibody-mediated Rejection.

Authors:  Shannon R Reese; Nancy A Wilson; Yabing Huang; Lucille Ptak; Kenna R Degner; Ding Xiang; Robert R Redfield; Weixiong Zhong; Sarah E Panzer
Journal:  Transplantation       Date:  2021-07-01       Impact factor: 5.385

Review 3.  Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage.

Authors:  Rossana Franzin; Alessandra Stasi; Marco Fiorentino; Giovanni Stallone; Vincenzo Cantaluppi; Loreto Gesualdo; Giuseppe Castellano
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

4.  Proteinuria is accompanied by intratubular complement activation and apical membrane deposition of C3dg and C5b-9 in kidney transplant recipients.

Authors:  Gustaf L Isaksson; Marie B Nielsen; Gitte R Hinrichs; Nicoline V Krogstrup; Rikke Zachar; Heidi Stubmark; Per Svenningsen; Kirsten Madsen; Claus Bistrup; Bente Jespersen; Henrik Birn; Yaseelan Palarasah; Boye L Jensen
Journal:  Am J Physiol Renal Physiol       Date:  2021-12-20

5.  Complement Activation via the Lectin and Alternative Pathway in Patients With Severe COVID-19.

Authors:  Janina Niederreiter; Christine Eck; Tajana Ries; Arndt Hartmann; Bruno Märkl; Maike Büttner-Herold; Kerstin Amann; Christoph Daniel
Journal:  Front Immunol       Date:  2022-02-02       Impact factor: 7.561

6.  A potent truncated form of human soluble CR1 is protective in a mouse model of renal ischemia-reperfusion injury.

Authors:  Anjan K Bongoni; Ingela B Vikstrom; Jennifer L McRae; Evelyn J Salvaris; Nella Fisicaro; Martin J Pearse; Sandra Wymann; Tony Rowe; Adriana Baz Morelli; Matthew P Hardy; Peter J Cowan
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

7.  Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.

Authors:  Gesa Tiller; Rosa G M Lammerts; Jessy J Karijosemito; Firas F Alkaff; Arjan Diepstra; Robert A Pol; Anita H Meter-Arkema; Marc A Seelen; Marius C van den Heuvel; Bouke G Hepkema; Mohamed R Daha; Jacob van den Born; Stefan P Berger
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

8.  The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation.

Authors:  Bénédicte Puissant-Lubrano; Charlène Bouthemy; Nicolas Congy-Jolivet; Jean Milhes; Vincent Minville; Nassim Kamar; Leïla Demini; Franck Zal; Yves Renaudineau
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

Review 9.  Complement Components in the Diagnosis and Treatment after Kidney Transplantation-Is There a Missing Link?

Authors:  Małgorzata Kielar; Agnieszka Gala-Błądzińska; Paulina Dumnicka; Piotr Ceranowicz; Maria Kapusta; Beata Naumnik; Grzegorz Kubiak; Marek Kuźniewski; Beata Kuśnierz-Cabala
Journal:  Biomolecules       Date:  2021-05-21

Review 10.  Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction.

Authors:  Marco Quaglia; Guido Merlotti; Gabriele Guglielmetti; Giuseppe Castellano; Vincenzo Cantaluppi
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.